Jane Street Group LLC Has $134,000 Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Jane Street Group LLC lowered its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 85.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 85,361 shares of the biopharmaceutical company’s stock after selling 521,195 shares during the period. Jane Street Group LLC’s holdings in Lexicon Pharmaceuticals were worth $134,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. State Street Corp boosted its stake in shares of Lexicon Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock valued at $3,880,000 after buying an additional 157,738 shares during the period. Atom Investors LP acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at $122,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at $189,000. BBR Partners LLC boosted its stake in shares of Lexicon Pharmaceuticals by 74.1% during the 3rd quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 200,000 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 13,246 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on LXRX. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, December 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Stock Down 7.9 %

LXRX stock opened at $0.71 on Tuesday. The firm has a market cap of $173.79 million, a PE ratio of -0.94 and a beta of 1.06. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.62 and a 1 year high of $3.73. The company has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $1.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period in the prior year, the firm earned ($0.21) EPS. Sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.